Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00678106 · ClinicalTrials.gov registry record · Phase 1

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target

NCT00678106: Completed Phase 1 study, sponsored by Pfizer.

NCT00678106 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00678106, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target

Study Summary

Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalbavancin.

Interventions

  • DRUG Dalbavancin

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2008-09
Est. Completion 2009-07
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT00678106 record still lists

NCT00678106 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 1 intervention - of which Dalbavancin is the first listed.

NCT00678106 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00678106 about?

NCT00678106 is a clinical study titled "Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections". Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalba...

What is the current status of trial NCT00678106?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-09. Estimated completion is 2009-07.

What interventions are being tested in trial NCT00678106?

The interventions under investigation include: Dalbavancin (DRUG).

Who is sponsoring clinical trial NCT00678106?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00678106's enrollment target sits among peer trials

10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00678106, the US trial registry maintained by the National Library of Medicine. NCT00678106 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.